March 21, 2023

Study Identifies Factors Predicting Tumor Upstaging in Esophageal Cancer

Dysphagia and SUVmax are predictive, but other suspected factors are not

Esophageal cancer, illustration

Esophageal cancer is an aggressive malignancy that is on the rise. It is especially difficult to diagnose at the early T2N0 stage, which can make it hard for physicians to know whether the patient should go directly to surgery or undergo chemo- and radiotherapy first. Now a new Cleveland Clinic study has identified key features for improving diagnosis and guiding treatment decisions.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Specifically, the researchers found that the presence of preoperative dysphagia and a maximum standardized uptake value (SUVmax) for the tumor of 5 or higher on PET scan predict upstaging — indicating that the patient would benefit from multimodal treatment.

“If we can recognize these high-risk markers for upstaging preoperatively, we can offer patients neoadjuvant therapy,” says Sadia Tasnim, MD, a Cleveland Clinic thoracic surgery research fellow and first author of the study, which was presented at the 2023 annual meeting of the Society of Thoracic Surgeons.

Disease stage is critical

The findings are important because esophageal cancer rarely presents at the T2N0 stage, when it is most treatable.

True T2N0 patients should undergo up-front surgery, whereas patients who have underlying advanced disease beyond T2N0 benefit more from multimodal therapy, notes Cleveland Clinic thoracic surgeon Monisha Sudarshan, MD, MPH, the study’s principal investigator.

“It’s important to accurately diagnose the stage,” Dr. Sudarshan explains, “because if we believe someone is T2N0 and they undergo surgery, and we find out later that they’re actually beyond T2N0, then we have not given them the advantage of chemotherapy and radiation preoperatively. That impacts their overall survival.”

However, she adds, physicians currently have few reliable tools to accurately diagnose a T2N0 esophageal cancer, due to limitations in endoscopic staging.

Advertisement

One of the largest studies to date

Some small retrospective studies have previously looked at this issue, but Dr. Sudarshan notes that no prior study comprehensively analyzed preoperative factors that can predict pathologic upstaging of cT2N0M0 esophageal cancer.

The Cleveland Clinic study identified 60 patients who underwent up-front surgery for clinical T2N0 esophageal cancer between 2000 and 2020. Patients who received chemotherapy and radiation were excluded. The researchers looked at the relationship between different variables and tumor upstaging.

Figure. Partial dependence plot predicting upstaging by SUVmax stratified by the presence of preoperative dysphagia.

Dr. Tasnim says they expected that dysphagia and higher SUVmax would be predictors of upstaging (see Figure). They were surprised, however, that other factors — including tumor size and the presence of strictures on endoscopy — were not predictors.

This could be a limitation of the sample size, Dr. Sudarshan points out, but she adds that this is actually one of the larger studies of the subset of patients who have this rarely diagnosed stage of cancer. “T2N0 is a stage at which you can still do quite a bit of good for these patients, as it is so early,” she says. “So these patients are a small but important group.”

More research ahead

Next, the team plans to continue its research by gathering more data to gain better insights.

Advertisement

“For example,” Dr. Sudarshan notes, “the presence of ulcer showed a trend toward upstaging, but this trend was not statistically significant. We wonder if that is just because we didn’t have enough patients, so we plan to recruit more patients and do a follow-up investigation.”

“In the meantime,” she continues, “this study’s findings have impacted the way we manage patients with T2N0 esophageal cancer. If we see patients with this stage of cancer who have difficulty swallowing or a high SUVmax, they will likely get preoperative chemoradiotherapy.”

“As we continue to understand and appreciate the nuances of esophageal cancer presentation,” adds study co-author Sudish Murthy, MD, PhD, Section Head of Thoracic Surgery at Cleveland Clinic, “the era of personalized esophageal cancer care becomes a clear target for patients.”

Related Articles

URL_Mould_3486624_NanoKnife with Patient in OR_12-20-22_MLC
February 13, 2023
Minimally Invasive Focal Therapy Promising Approach for Select Patients with Prostate Cancer

A newer modality for select patients has shown positive outcomes to date

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

CQD-CHP4445461-hanna-sickle-650×450
February 5, 2024
Haploidentical Bone Marrow Transplant Has Durable Engraftment in Patients With Sickle Cell Disease

Two-year event-free survival comparable to matched sibling donor myeloablative transplant

24-CNR-4545611-CQD-Podcast-967×544
February 1, 2024
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

Ad